Applied Spine Technologies announces first patient surgery to test safety and effectiveness of Stabilimax system

Applied Spine Technologies (www.appliedspine.com) announces the first patient surgery at Allegheny General Hospital in Pittsburgh, Pennsylvania, as part of their FDA approved Investigational Device Exemption (IDE) clinical trial designed to evaluate the safety and effectiveness of the Stabilimax® Dynamic Spine Stabilization System. The surgery was performed by Donald M. Whiting, M.D. on October 26th. Allegheny General Hospital is the latest clinical site to participate in the Stabilimax trial.

“We are very pleased to welcome Dr. Whiting and the entire spine team at Allegheny General as our newest investigational site,” said Craig Corrance, Chief Executive Officer of Applied Spine. “Allegheny General Hospital’s status as a nationally recognized comprehensive spine Center of Excellence reflects our strategy of partnering with leading U.S. spine facilities for the duration of our IDE clinical trial.”